Drugs, non-drugs, and disease category specificity: organ effects by ligand pharmacology1
暂无分享,去创建一个
[1] David S. Wishart,et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets , 2007, Nucleic Acids Res..
[2] Yasuo Ohashi,et al. Overlap coefficient for assessing the similarity of pharmacokinetic data between ethnically different populations , 2005, Clinical trials.
[3] F. Markowetz,et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.
[4] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[5] Uko Maran,et al. Drug efficiency indices for improvement of molecular docking scoring functions , 2010, J. Comput. Chem..
[6] Alfonso T García-Sosa,et al. Free Energy Calculations of Mutations Involving a Tightly Bound Water Molecule and Ligand Substitutions in a Ligand‐Protein Complex , 2010, Molecular informatics.
[7] Uko Maran,et al. Combined Approach Using Ligand Efficiency, Cross-Docking, and Antitarget Hits for Wild-Type and Drug-Resistant Y181C HIV-1 Reverse Transcriptase , 2011, J. Chem. Inf. Model..
[8] Yuan Zhao,et al. Computation of Octanol-Water Partition Coefficients by Guiding an Additive Model with Knowledge , 2007, J. Chem. Inf. Model..
[9] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[10] A. Hopkins,et al. Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.
[11] David S. Wishart,et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..
[12] Meir Glick,et al. Prediction of Biological Targets for Compounds Using Multiple-Category Bayesian Models Trained on Chemogenomics Databases , 2006, J. Chem. Inf. Model..
[13] Renxiao Wang,et al. The PDBbind database: collection of binding affinities for protein-ligand complexes with known three-dimensional structures. , 2004, Journal of medicinal chemistry.
[14] J. Chambers. A Concise Course in Advanced Level Statistics , 1984 .
[15] P. Bork,et al. Drug Target Identification Using Side-Effect Similarity , 2008, Science.
[16] Uko Maran,et al. Docking and Virtual Screening Using Distributed Grid Technology , 2009 .
[17] O. Taboureau,et al. The impact of network biology in pharmacology and toxicology , 2012, SAR and QSAR in environmental research.
[18] Uko Maran,et al. DrugLogit: Logistic Discrimination between Drugs and Nondrugs Including Disease-Specificity by Assigning Probabilities Based on Molecular Properties , 2012, J. Chem. Inf. Model..
[19] I. Kuntz,et al. The maximal affinity of ligands. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[20] Junwei Zhang,et al. Development of KiBank, a database supporting structure-based drug design , 2004, Comput. Biol. Chem..
[21] A. Bender,et al. Modeling Promiscuity Based on in vitro Safety Pharmacology Profiling Data , 2007, ChemMedChem.
[22] U. Maran,et al. Molecular property filters describing pharmacokinetics and drug binding. , 2012, Current medicinal chemistry.
[23] Alfonso T. García-Sosa,et al. Structure-based calculation of drug efficiency indices , 2007, Bioinform..
[24] Michael J. Keiser,et al. The Chemical Basis of Pharmacology , 2010, Biochemistry.
[25] Uko Maran,et al. Disease‐Specific Differentiation Between Drugs and Non‐Drugs Using Principal Component Analysis of Their Molecular Descriptor Space , 2012, Molecular informatics.
[26] J. Ladbury,et al. Survey of the year 2005: literature on applications of isothermal titration calorimetry , 2007, Journal of molecular recognition : JMR.
[27] B. Matthews. Comparison of the predicted and observed secondary structure of T4 phage lysozyme. , 1975, Biochimica et biophysica acta.